Fig. 3.

Antibody binding to HM-SGM-v2. The HM-SGM-v2 was characterized with (A) anti-type 1 antibody (concentration unknown), (B) anti-H type 1 antibody (1:10 dilution), (C) anti-Le^a antibody (10 μg/ml), (D) anti-Le^b antibody (10 μg/ml), (E) anti-SLe^a/LSTa (NeuAcα2–3Galβ1–3GlcNAcβ1–3Galβ1–4Glc antibody, 5 μg/ml), (F) anti-Le^x antibody (1:20 dilution), (G) anti-CD15 antibody (10 μg/ml), (H) anti-Le^y antibody (50 μg/ml), and (I) anti-CSlex antibody (20 μg/ml). A total of 260 samples were printed on the microarray. Glycans 1–88 are neutral glycans, 89–96 are unresolved fractions of neutral glycans, 97–207 are monosialyl glycans, 208–234 are disialyl glycans, 235–247 are unresolved fractions of sialylated glycans, 248–259 are controls of structurally defined glycans, and 260 is biotin control. All glycans were printed at the same concentration; however, unresolved fractions will not represent single glycans.